Achaogen Inc (NASDAQ:AKAO) – Equities researchers at Gabelli issued their FY2017 EPS estimates for shares of Achaogen in a research report issued on Tuesday. Gabelli analyst K. Kedra anticipates that the biopharmaceutical company will earn ($2.70) per share for the year. Gabelli also issued estimates for Achaogen’s FY2018 earnings at ($2.00) EPS, FY2019 earnings at ($0.85) EPS, FY2020 earnings at $0.75 EPS and FY2021 earnings at $3.25 EPS.

Achaogen (NASDAQ:AKAO) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.39. The business had revenue of $7.46 million for the quarter, compared to analysts’ expectations of $3.81 million. Achaogen had a negative return on equity of 143.44% and a negative net margin of 147.80%. The business’s revenue was up 27.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.66) earnings per share.

ILLEGAL ACTIVITY NOTICE: “Achaogen Inc (AKAO) Expected to Earn FY2017 Earnings of ($2.70) Per Share” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/05/11/achaogen-inc-akao-expected-to-earn-fy2017-earnings-of-2-70-per-share.html.

Earnings History and Estimates for Achaogen (NASDAQ:AKAO)

Several other research firms have also issued reports on AKAO. Stifel Nicolaus reissued a “buy” rating and set a $31.00 price target (up from $28.00) on shares of Achaogen in a research report on Tuesday. Aegis lowered Achaogen from a “buy” rating to a “hold” rating and set a $29.00 price target on the stock. in a research report on Thursday, March 30th. Zacks Investment Research raised Achaogen from a “hold” rating to a “buy” rating and set a $23.00 price target on the stock in a research report on Monday, February 13th. Guggenheim reissued a “buy” rating and set a $30.00 price target on shares of Achaogen in a research report on Tuesday, January 24th. Finally, Cowen and Company reissued an “outperform” rating on shares of Achaogen in a research report on Friday, May 5th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $25.20.

Shares of Achaogen (NASDAQ:AKAO) traded up 1.747% during trading on Thursday, hitting $22.944. 102,647 shares of the stock were exchanged. The stock’s market cap is $822.61 million. Achaogen has a one year low of $2.69 and a one year high of $27.79. The stock’s 50 day moving average price is $22.92 and its 200 day moving average price is $16.39.

Large investors have recently modified their holdings of the company. Bank of Montreal Can raised its stake in shares of Achaogen by 25.0% in the first quarter. Bank of Montreal Can now owns 7,500 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 1,500 shares in the last quarter. Bank of New York Mellon Corp raised its stake in shares of Achaogen by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 113,783 shares of the biopharmaceutical company’s stock valued at $2,871,000 after buying an additional 3,150 shares in the last quarter. Hartwell J M Limited Partnership raised its stake in shares of Achaogen by 21.2% in the first quarter. Hartwell J M Limited Partnership now owns 20,000 shares of the biopharmaceutical company’s stock valued at $505,000 after buying an additional 3,500 shares in the last quarter. Sigma Planning Corp bought a new stake in shares of Achaogen during the first quarter valued at $218,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Achaogen during the first quarter valued at $240,000. 44.47% of the stock is currently owned by hedge funds and other institutional investors.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).

5 Day Chart for NASDAQ:AKAO

Receive News & Ratings for Achaogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.